Medunik Canada, is an orphan drug company dedicated to helping Canadians with rare
diseases access therapies currently unavailable in Canada. Medunik
Canada is proud to announce that it has signed an exclusive
distribution agreement with Orphan Europe Recordati Group. Under this
agreement, Medunik Canada receives the exclusive Canadian rights to
market and distribute four important therapies in the following medical
conditions: (1) acute hepatic porphyria, (2) hyperammonaema due to
N-acetylglutamate synthase (NAGS) deficiency or one of three organic
acidurias (isovaleric, methylmalonic or propionic), (3) patent ductus
arteriosus and (4) vitamin E deficiency in chronic cholestasis.
"We are thrilled to enter into a new partnership with Orphan Europe
Recordati Group" stated Éric Gervais, Executive Vice-President of
Medunik Canada. "This new strategic collaboration complements our
existing alliances and represents an important milestone in our
endeavor to help patients with a rare disease in Canada to benefit from
the best treatments available".
Marco Liguori, General Manager & Recordati Vice-President, Special care
and Orphan Drugs went on to say that "Orphan Europe Recordati Group is
delighted to extend its products and services to rare disease patients
in Canada. We are particularly happy to work with a company like
Medunik Canada which is committed to building awareness and promoting
better diagnosis and care of rare disease patients in Canada."
Why predictive retina models could be the future of IND applications